Metabolon has assembled an outstanding group of talented and experienced managers to develop and execute the business plan. We have also assembled an impressive science staff that includes specialists in biochemistry, mass spectrometry and software development.
John Ryals, Ph.D.
Board Member, President and Chief Executive Officer
Dr. Ryals received a Ph.D. in Molecular Biology from the University of Texas at
Dallas. Prior to joining Metabolon, Dr. Ryals was CEO, president and founder of
Paradigm Genetics, Inc. (NASDAQ:PDGM). There, he raised over $100 million in equity
financing, including an Initial Public Offering in 2000 and a follow on offering
in 2001 and closed on R&D partnerships valued at over $200 million. Dr. Ryals has
20 years of experience in the biotechnology industry including senior research positions
at Novartis and Ciba-Geigy and currently serves on the Board of North Carolina State
University College of Physical and Mathematical Sciences.
S. Todd Lynch, CPA
Chief Financial Officer
Mr. Lynch is a certified public accountant with 20 years of executive and financial
experience with life science companies and public accounting. Prior to joining Metabolon,
Mr. Lynch was vice president, global finance for the clinical division of Inveresk,
a contract research organization and subsidiary of Charles River Laboratories. Mr.
Lynch also served in various financial roles for GlaxoSmithKline and gained seven
years of public accounting experience with Coopers & Lybrand specializing in healthcare
and manufacturing.
Michael (Mike) Milburn, Ph.D.
Chief Scientific Officer
Dr. Milburn received his Ph.D. in Biophysical Chemistry at the University of California, Berkeley and was a research fellow at Harvard Medical School for his post-doctoral work. Dr. Milburn has over 20 years of experience in biotech and pharmaceutical companies including over 10 years in senior biotechnology research positions. Dr. Milburn has published over 100 scientific articles on technology, research and development in the life sciences. Before joining Metabolon, Dr. Milburn was Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals where he led the preclinical/clinical development of drugs in the areas of metabolic disease and neurodegeneration. Sirtris Pharmaceuticals pioneered the discovery of drug agents targeting the Sirtuin enzyme family involved in aging diseases and the company was acquired by GSK in 2007. Prior to Sirtris, Dr. Milburn was Senior Vice President of Research at Plexxikon and was responsible for the development of Plexxikon's proprietary high-throughput scaffold-based chemical technology platform. While at Plexxikon, Dr. Milburn developed lead preclinical and clinical programs in the areas of metabolic disease and cancer. At Metabolon, Dr. Milburn is currently Chief Scientific Officer and is responsible for the global metabolomics technology development and research operations for its service business. Dr. Milburn’s group works with over 300 clients at Metabolon and has completed over 1000 commercial studies since 2005. Metabolon’s research group has published over 50 peer-reviewed articles with many of Metabolon’s clients.
Chris Bernard
Senior Vice President, Sales and Marketing
Mr. Bernard joined Metabolon in August 2009 to direct the expansion and management
of its service business. He is a flexible, innovative leader with 15+ years of sales
and marketing experience and a proven track record of building high performing teams
able to deliver business critical results under aggressive timelines. Mr. Bernard
came to Metabolon from Abaxis Inc, where as Vice President of Sales and Marketing
he built the sales, marketing, technical and customer service groups for the medical
diagnostic business. Prior to that, from 1995 to 2005, Mr. Bernard held various
sales and sales management positions at Cytyc Corp, now Hologic. He finished his
career at Cytyc as a Regional Business Director. Mr. Bernard holds a bachelor’s
degree in psychobiology from Hiram College, is a board certified Cytologist; and
is currently on the board of directors for the Hiram College Integrated Entrepreneurship
Program.